文献速递新发突发、热带与寄生虫病

含或不含胡椒基丁醚的长效杀虫蚊帐对乌干达疟疾指标的影响(LLINEUP):嵌入全国分发活动的整群随机试验最终结果

Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution campaign.
PubMed 文献 · Lancet Infect Dis · 2022-09-26

LLINEUP是在乌干达东部和西部48个区开展的整群随机试验,比较含胡椒基丁醚(PBO)长效杀虫蚊帐与常规长效杀虫蚊帐对2-10岁儿童疟原虫患病率的影响。25个月时,PBO组长效杀虫蚊帐的疟原虫患病率为17.1%,非PBO组为19.8%,校正基线后的患病率比为0.80(95%CI 0.69-0.93),PBO组长效杀虫蚊帐优于仅含拟除虫菊酯的长效杀虫蚊帐。WHO据此作出条件性推荐,建议在拟除虫菊酯抗性高的地区部署PBO长效杀虫蚊帐。

要点

  • 25个月时,PBO组长效杀虫蚊帐的疟原虫患病率为17.1%,非PBO组为19.8%,校正基线后的患病率比为0.80(95%CI 0.69-0.93)。
  • 与基线相比,PBO组长效杀虫蚊帐在6个月时的患病率比为0.43(95%CI 0.36-0.52),25个月时为0.63(95%CI 0.57-0.71)。
  • WHO条件性推荐:在拟除虫菊酯抗性高的地区,PBO长效杀虫蚊帐比非PBO长效杀虫蚊帐更有效。

核心结论

  • 在乌干达,含PBO的长效杀虫蚊帐在25个月内优于仅含拟除虫菊酯的长效杀虫蚊帐。

研究设计与样本

  • LLINEUP是一项在乌干达东部和西部48个区开展的整群随机试验。
  • 104个无正在或计划开展室内滞留喷洒(使用甲基嘧啶磷)的卫生分区(整群)被纳入试验。
  • 整群按比例随机分配至PBO长效杀虫蚊帐(PermaNet 3.0或Olyset Plus)组和常规长效杀虫蚊帐(PermaNet 2.0或Olyset Net)组,随机化使用STATA 14.2版。
  • 长效杀虫蚊帐于2017年3月25日至2018年3月18日发放。
  • 2019年4月23日至9月13日,在每个整群随机选取50户家庭开展社区调查;每个整群随机选取10户家庭开展昆虫学调查。

主要发现

  • 按实际治疗分析中,2个整群被排除(未接受占主导的长效杀虫蚊帐类型),4个整群被重新分配;最终纳入40个PBO长效杀虫蚊帐整群(30个PermaNet 3.0,10个Olyset Plus)和48个非PBO长效杀虫蚊帐整群(36个PermaNet 2.0,12个Olyset Net)。
  • PBO组长效杀虫蚊帐的疟原虫患病率为17.1%(2958名参与者中506例),非PBO组长效杀虫蚊帐为19.8%(3534名参与者中701例),校正基线后的患病率比为0.80(95%CI 0.69-0.93),p=0.0048。
  • PBO组长效杀虫蚊帐基线患病率为28.8%(3472名中1001例,95%CI 27.3-30.4),6个月时为12.0%(3009名中361例,95%CI 10.9-13.2),患病率比0.43(95%CI 0.36-0.52),p<0.0001。
  • 非PBO组长效杀虫蚊帐基线患病率为25.4%(4004名中1015例,95%CI 24.0-26.7),6个月时为14.8%(3551名中526例,95%CI 13.7-16.0),患病率比0.60(95%CI 0.54-0.68),p<0.0001。
  • PBO组长效杀虫蚊帐25个月时患病率为17.1%(2958名中506例,95%CI 15.8-18.5),患病率比0.63(95%CI 0.57-0.71),p<0.0001;非PBO组长效杀虫蚊帐25个月时为19.8%(3534名中701例,95%CI 18.5-21.2),患病率比0.79(95%CI 0.73-0.86),p<0.0001。

关键数值与推荐

  • WHO结论:在拟除虫菊酯抗性高的情况下,PBO长效杀虫蚊帐比非PBO长效杀虫蚊帐更有效;并作出条件性推荐,建议在拟除虫菊酯抗性地区部署PBO长效杀虫蚊帐。

临床怎么用

  • WHO条件性推荐建议在拟除虫菊酯抗性高的地区部署PBO长效杀虫蚊帐。

局限性

  • 受COVID-19限制,25个月时仅调查了104个整群中的90个。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-lasting insecticidal nets (LLINs) are the foundation of malaria control but resistance of mosquito vectors to pyrethroids threatens their effectiveness. We embedded a cluster-randomised trial into Uganda's 2017-18 campaign to distribute LLINs. LLINs with piperonyl butoxide (PBO) reduced parasite prevalence more effectively than conventional LLINs (without PBO) for 18 months. Here, we report the final 25-month survey results. METHODS: LLINEUP was a cluster-randomised trial conducted in 48 districts in eastern and western Uganda. 104 health subdistricts (clusters) without ongoing or planned indoor residual spraying with pirimiphos-methyl (Actellic, Basel, Switzerland) were eligible for inclusion in the trial. Clusters were randomly assigned to PBO LLINs (PermaNet 3.0 or Olyset Plus) and conventional LLINs (PermaNet 2.0 or Olyset Net) with proportionate randomisation using STATA version 14.2. LLINs were delivered from March 25, 2017, to March 18, 2018. Between April 23, 2019, and Sept 13, 2019, community surveys were conducted in 50 randomly selected households per cluster; ten households per cluster were randomly selected for entomology surveys. Mosquitoes were collected in the morning from indoor surfaces of households using Prokopack aspirators. Due to COVID-19 restrictions, only 90 of the 104 clusters were surveyed at 25 months. The primary outcome was parasite prevalence by microscopy in children aged 2-10 years, assessed in the as-treated population, determined using the results from the 6-month household survey on the type of LLINs received in each cluster. This trial is registered with ISRCTN, ISRCTN17516395, and is now completed. FINDINGS: In the as-treated analysis, two clusters were excluded (no predominant LLIN received) and four were reassigned; 40 PBO LLIN clusters (30 PermaNet 3.0, ten Olyset Plus) and 48 non-PBO LLIN (36 PermaNet 2.0, 12 Olyset Net) were included. Parasite prevalence was 17·1% (506 of 2958 participants) in the PBO group and 19·8% (701 of 3534) in the non-PBO group (prevalence ratio adjusted for baseline 0·80 [95% CI 0·69-0·93], p=0·0048). Comparing within-treatment group parasite prevalence to baseline, parasite prevalence ratios were lower in the PBO groups at all timepoints, but the difference was greatest at 6 months (PBO LLINs parasite prevalence at baseline 28·8% [1001 of 3472, 95% CI 27·3-30·4] vs at 6 months 12·0% [361 of 3009, 10·9-13·2], prevalence ratio [PR] 0·43 [95% CI 0·36-0·52], p<0·0001; non-PBO LLINs parasite prevalence at baseline 25·4% [1015 of 4004, 24·0-26·7] vs 6 months 14·8% [526 of 3551, 13·7-16·0], PR 0·60 [0·54-0·68], p<0·0001) and 25 months (PBO LLINs parasite prevalence at 25 months 17·1% [506 of 2958, 15·8-18·5], PR 0·63 [95% CI 0·57-0·71], p<0·0001; non-PBO LLINs parasite prevalence at 25 months 19·8% [701 of 3534, 18·5-21·2], PR 0·79 [0·73-0·86], p<0·0001). INTERPRETATION: In Uganda, PBO LLINs outperformed pyrethroid-only LLINs for 25 months. WHO concluded that PBO LLINs are more effective against malaria than non-PBO LLINs when resistance to pyrethroids is high and issued a conditional recommendation suggesting PBO LLINs should be deployed in areas of pyrethroid resistance. FUNDING: The Against Malaria Foundation, UK Department for International Development, Innovative Vector Control Consortium, and Bill and Melinda Gates Foundation.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Maiteki-Sebuguzi C, Gonahasa S, Kamya MR, et al. Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution campaign. Lancet Infect Dis. 2022. PMID: 36174592. doi:10.1016/S1473-3099(22)00469-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。